Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab Oncology's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 42.41.
Alphamab Oncology's Days Inventory for the
six
months ended in Dec. 2025 was 535.76.
Alphamab Oncology's Days Payable for the
six
months ended in Dec. 2025 was 349.15.
Therefore, Alphamab Oncology's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 229.02.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Alphamab Oncology Cash Conversion Cycle Related Terms
Alphamab Oncology Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3NK vs VRTX, REGN, RVMD: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Alphamab Oncology's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Alphamab Oncology's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (FRA:3NK) has a Cash Conversion Cycle of 229.02 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Alphamab Oncology and its competitors.
Is Alphamab Oncology's Cash Conversion Cycle too high?
Alphamab Oncology's current Cash Conversion Cycle is 229.02. The Biotechnology industry median Cash Conversion Cycle is 105.96. Alphamab Oncology's value of 229.02 is 116.1% above this industry median. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Cash Conversion Cycle compare to VRTX and REGN?
Alphamab Oncology's Cash Conversion Cycle of 229.02 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 105.96. Alphamab Oncology's value of 229.02 is 116.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 105.96, based on 874 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alphamab Oncology's current Cash Conversion Cycle of 229.02 is 116.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Alphamab Oncology and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 105.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphamab Oncology's current Cash Conversion Cycle is 229.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (FRA:3NK) has a current Cash Conversion Cycle of 229.02. The stock's GF Value™ is €0.82, compared to a current price of €0.88 — trading 7.3% above its estimated fair value. The current Cash Conversion Cycle is 229.02 and 116.1% above the Biotechnology industry median of 105.96. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Alphamab Oncology (FRA:3NK), the current Cash Conversion Cycle is 229.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.
Key valuation signals for FRA:3NK:
Cash Conversion Cycle: 229.02
GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
Industry Position: 116.1% above the Biotechnology median
No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for FRA:3NK
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3NK has been successfully added to your 
